In vitro metabolism of N′-Nitrosonornicotine catalyzed by cytochrome P450 2A13 and its inhibition by nicotine, N′-Nitrosoanatabine and N′-Nitrosoanabasine

Chemico-Biological Interactions

Volumn 260, Issue , 2016, Pages 263-269

  Liu, Xingyu ^a   Zhang, Jie ^a   Wang, Limeng ^b   Yang, Bicheng ^c   Zhang, Chen ^a   Liu, Wei ^a   Zhou, Jun ^a  

^a Beijing Work Station   (China)

^b DALIAN INSTITUTE OF CHEMICAL PHYSICS   (China)

^c JIANGXI PROVINCIAL MATERNAL AND CHILD HEALTH HOSPITAL   (China)

Author keywords

Cytochrome P450; Inhibition; Metabolism; NNN

Indexed keywords

4 HYDROXY 1 (3 PYRIDYL) 1 BUTANONE; 4 HYDROXY 4 (3 PYRIDYL)BUTYRIC ACID(HYDROXY ACID); 4 OXO 4 (3 PYRIDYL)BUTANAL; CHEMICAL COMPOUND; CYTOCHROME P450; CYTOCHROME P450 2A13; CYTOCHROME P450 2A6; HYDROXYACID; N' NITROSOANABASINE; N' NITROSOANATABINE; NICOTINE; NITROSAMINE; NITROSONORNICOTINE; UNCLASSIFIED DRUG; 4-HYDROXY-1-(3-PYRIDYL)-1-BUTANONE; ALKANONE; CYP2A13 PROTEIN, HUMAN; N'-NITROSOANABASINE; N'-NITROSOANATABINE; N'-NITROSONORNICOTINE; PYRIDINE DERIVATIVE; UNSPECIFIC MONOOXYGENASE;

ARTICLE; COMPARATIVE STUDY; COMPETITIVE INHIBITION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; ENZYME KINETICS; IN VITRO STUDY; INHIBITION CONSTANT; MASS SPECTROMETRY; METABOLIC REGULATION; MICHAELIS MENTEN KINETICS; MOLECULAR INTERACTION; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; SYNTHESIS; ANTAGONISTS AND INHIBITORS; BIOCATALYSIS; DRUG EFFECTS; HUMAN; KINETICS; METABOLISM; METABOLOME;

ARYL HYDROCARBON HYDROXYLASES; BIOCATALYSIS; BUTANONES; HUMANS; KINETICS; METABOLIC NETWORKS AND PATHWAYS; METABOLOME; NICOTINE; NITROSAMINES; PYRIDINES;

EID: 84995514196     PISSN: 00092797     EISSN: 18727786     Source Type: Journal    
DOI: 10.1016/j.cbi.2016.08.017     Document Type: Article

References (48)

1. [1] Hecht, S.S., Hoffmann, D., Tobacco-specific nitrosamines, an important group of carcinogens in tobacco and tobacco smoke. Carcinogenesis 9 (1988), 875–884.
2. [2] Osterdahl, B.G., Jansson, C., Paccou, A., Decreased levels of tobacco-specific N-nitrosamines in moist snuff on the Swedish market. J. Agric. Food Chem. 52 (2004), 5085–5088.
3. [3] Stanfill, S.B., Connolly, G.N., Zhang, L., Jia, L.T., Henningfield, J.E., Richter, P., Lawler, T.S., Ayo-Yusuf, O.A., Ashley, D.L., Watson, C.H., Global surveillance of oral tobacco products: total nicotine, unionised nicotine and tobacco-specific N-nitrosamines. Tob. Control 20 (2011), 1–10.
4. [4] Hecht, S.S., Chen, C.B., Hirota, N., Ornaf, R.M., Tso, T.C., Hoffmann, D., Tobacco-specific nitrosamines: formation from nicotine in vitro and during tobacco curing and carcinogenicity in strain A mice. J. Natl. Cancer Inst. 60 (1978), 819–824.
5. [5] Moldoveanu, S.C., Borgerding, M., Formation of tobacco specific nitrosamines in mainstream cigarette smoke; part 1, FTC smoking. Beitr. Zur. Tab. Int. 23 (2008), 19–31.
6. [6] Tricker, A.R., Haubner, R., Spiegelhalder, B., Preussmann, R., The occurrence of tobacco-specific nitrosamines in oral tobacco products and their potential formation under simulated gastric conditions. Food Chem. Toxicol. 26 (1988), 861–865.
7. [7] IARC, Agents Classified by the IARC Monographs, vols. 1–111, 2012.
8. [8] Hecht, S.S., Biochemistry, biology, and carcinogenicity of tobacco-specific N-Nitrosamines. Chem. Res. Toxicol. 11 (1998), 559–603.
9. [9] Rodgman, A., Green, C.R., Toxic chemicals in cigarette mainstream smoke - hazard and hoopla. Beitr. Zur. Tab. Int. 20 (2003), 481–543.
10. [10] Guo, Z., Smith, T.J., Thomas, P.E., Yang, C.S., Metabolism of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone by inducible and constitutive cytochrome P450 enzymes in rats. Arch. Biochem. Biophys. 298 (1992), 279–286.
11. [11] Smith, T.J., Guo, Z., Guengerich, F.P., Yang, C.S., Metabolism of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) by human cytochrome P450 1A2 and its inhibition by phenethyl isothiocyanate. Carcinogenesis 17 (1996), 809–813.
12. [12] Smith, T.J., Liao, A., Wang, L.D., Yang, G.Y., Starcic, S., Philbert, M.A., Yang, C.S., Characterization of xenobiotic-metabolizing enzymes and nitrosamine metabolism in the human esophagus. Carcinogenesis 19 (1998), 667–672.
13. [13] Danielson, P.B., The cytochrome P450 superfamily: biochemistry, evolution and drug metabolism in humans. Curr. Drug Metab. 3 (2002), 561–597.
14. [14] Jalas, J.R., Hecht, S.S., Murphy, S.E., Cytochrome P450 enzymes as catalysts of metabolism of 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone, a tobacco specific carcinogen. Chem. Res. Toxicol. 18 (2005), 95–110.
15. [15] Zhang, X., D'Agostino, J., Wu, H., Zhang, Q.Y., von Weymarn, L., Murphy, S.E., Ding, X., CYP2A13: variable expression and role in human lung microsomal metabolic activation of the tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. J. Pharmacol. Exp. Ther. 323 (2007), 570–578.
16. [16] Su, T., Bao, Z., Zhang, Q.Y., Smith, T.J., Hong, J.Y., Ding, X., Human cytochrome P450 CYP2A13: predominant expression in the respiratory tract and its high efficiency metabolic activation of a tobacco-specific carcinogen, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. Cancer Res. 60 (2000), 5074–5079.
17. [17] Smith, T.J., Stoner, G.D., Yang, C.S., Activation of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in human lung microsomes by cytochromes P450, lipoxygenase, and hydroperoxides. Cancer Res. 55 (1995), 5566–5573.
18. [18] Smith, T.J., Guo, Z., Gonzalez, F.J., Guengerich, F.P., Stoner, G.D., Yang, C.S., Metabolism of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in human lung and liver microsomes and cytochromes P-450 expressed in hepatoma cells. Cancer Res. 52 (1992), 1757–1763.
19. [19] Smith, G.B., Castonguay, A., Donnelly, P.J., Reid, K.R., Petsikas, D., Massey, T.E., Biotransformation of the tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in freshly isolated human lung cells. Carcinogenesis 20 (1999), 1809–1818.
20. [20] Smith, G.B., Bend, J.R., Bedard, L.L., Reid, K.R., Petsikas, D., Massey, T.E., Biotransformation of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in peripheral human lung microsomes. Drug Metab. Dispos. 31 (2003), 1134–1141.
21. [21] Peterson, L.A., Mathew, R., Hecht, S.S., Quantitation of microsomal alpha-hydroxylation of the tobacco-specific nitrosamine, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. Cancer Res. 51 (1991), 5495–5500.
22. [22] Patten, C.J., Smith, T.J., Murphy, S.E., Wang, M.H., Lee, J., Tynes, R.E., Koch, P., Yang, C.S., Kinetic analysis of the activation of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone by heterologously expressed human P450 enzymes and the effect of P450-specific chemical inhibitors on this activation in human liver microsomes. Arch. Biochem. Biophys. 333 (1996), 127–138.
23. [23] Megaraj, V., Zhou, X., Xie, F., Liu, Z., Yang, W., Ding, X., Role of CYP2A13 in the bioactivation and lung tumorigenicity of the tobacco-specific lung procarcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone: in vivo studies using a CYP2A13-humanized mouse model. Carcinogenesis 35 (2014), 131–137.
24. [24] Maser, E., Richter, E., Friebertshäuser, J., The identification of 11β-hydroxysteroid dehydrogenase as carbonyl reductase of the tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. FEBS J. 238 (1996), 484–489.
25. [25] Crespi, C.L., Penman, B.W., Gelboin, H.V., Gonzalez, F.J., A tobacco smoke-derived nitrosamine, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, is activated by multiple human cytochrome P450s including the polymorphic human cytochrome P4502D6. Carcinogenesis 12 (1991), 1197–1201.
26. [26] Prokopczyk, B., Trushin, N., Leszczynska, J., Waggoner, S.E., El-Bayoumy, K., Human cervical tissue metabolizes the tobacco-specific nitrosamine, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, via alpha-hydroxylation and carbonyl reduction pathways. Carcinogenesis 22 (2001), 107–114.
27. [27] Liu, X., Zhang, J., Zhang, C., Yang, B., Wang, L., Zhou, J., The inhibition of cytochrome P450 2A13-catalyzed NNK metabolism by NAT. NAB Nicotine Toxicol. Res., 2016, 10.1039/C1036TX00016A.
28. [28] Leslie, E.M., Ghibellini, G., Nezasa, K., Brouwer, K.L., Biotransformation and transport of the tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in bile duct-cannulated wild-type and Mrp2/Abcc2-deficient (TR) Wistar rats. Carcinogenesis 28 (2007), 2650–2656.
29. [29] Bao, Z., He, X.Y., Ding, X., Prabhu, S., Hong, J.Y., Metabolism of nicotine and cotinine by human cytochrome P450 2A13. Drug Metab. Dispos. 33 (2005), 258–261.
30. [30] Denton, T.T., Zhang, X., Cashman, J.R., Nicotine-related alkaloids and metabolites as inhibitors of human cytochrome P-450 2A6. Biochem. Pharmacol. 67 (2004), 751–756.
31. [31] von Weymarn, L.B., Brown, K.M., Murphy, S.E., Inactivation of CYP2A6 and CYP2A13 during nicotine metabolism. J. Pharmacol. Exp. Ther. 316 (2006), 295–303.
32. [32] Chung, F.L., Juchatz, A., Vitarius, J., Hecht, S.S., Effects of dietary compounds on alpha-hydroxylation of N-nitrosopyrrolidine and N′-nitrosonornicotine in rat target tissues. Cancer Res. 44 (1984), 2924–2928.
33. [33] Shi, S.T., Wang, Z.Y., Smith, T.J., Hong, J.Y., Chen, W.F., Ho, C.T., Yang, C.S., Effects of green tea and black tea on 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone bioactivation, DNA methylation, and lung tumorigenesis in A/J mice. Cancer Res. 54 (1994), 4641–4647.
34. [34] Keyler, D., Pentel, P.R., Kuehl, G., Collins, G., Murphy, S.E., Effects of nicotine infusion on the metabolism of the tobacco carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in rats. Cancer Lett. 202 (2003), 1–9.
35. [35] Jalas, J.R., Ding, X., Murphy, S.E., Comparative metabolism of the tobacco-specific introsamines 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone and 4-(methylnitrosamino)-1-butanol by rat cytochrome P450 2A3 and human cytochrome P450 2A13. Drug Metab. Dispos. 31 (2003), 1199–1202.
36. [36] Zhang, J., Bai, R., Yi, X., Yang, Z., Liu, X., Zhou, J., Liang, W., Fully automated analysis of four tobacco-specific N-nitrosamines in mainstream cigarette smoke using two-dimensional online solid phase extraction combined with liquid chromatography-tandem mass spectrometry. Talanta 146 (2016), 216–224.
37. [37] X. Liu, J. Zhang, L. Wang, B. Yang, C. Zhang, W. Liu, J. Zhou, HPLC-MS/MS analysis of metabolites of N′-Nitrosonornicotine catalyzed by cytochrome P450 2A13, (Data in Brief submitted).
38. [38] Yamazaki, H., Inui, Y., Yun, C.-H., Guengerich, F.P., Shimada, T., Cytochrome P450 2E1 and 2A6 enzymes as major catalysts for metabolic activation of N-nitrosodialkylamines and tobacco-related nitrosamines in human liver microsomes. Carcinogenesis 13 (1992), 1789–1794.
39. [39] Penman, B.W., Reece, J., Smith, T., Yang, C.S., Gelboin, H.V., Gonzalez, F.J., Crespi, C.L., Characterization of a human cell line expressing high levels of cDNA-derived CYP2D6. Pharmacogenetics 3 (1993), 28–39.
40. [40] Maser, E., Friebertshauser, J., Volker, B., Purification, characterization and NNK carbonyl reductase activities of 11beta-hydroxysteroid dehydrogenase type 1 from human liver: enzyme cooperativity and significance in the detoxification of a tobacco-derived carcinogen. Chem. Biol. Interact. 143–144 (2003), 435–448.
41. [41] Maser, E., Significance of reductases in the detoxification of the tobacco-specific carcinogen NNK. Trends Pharmacol. Sci. 25 (2004), 235–237.
42. [42] Carmella, S.G., Han, S., Villalta, P.W., Hecht, S.S., Analysis of total 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol in smokers' blood. Cancer Epidemiol. Biomark. Prev. 14 (2005), 2669–2672.
43. [43] Morin, A., Shepperd, C.J., Eldridge, A.C., Poirier, N., Voisine, R., Estimation and correlation of cigarette smoke exposure in Canadian smokers as determined by filter analysis and biomarkers of exposure. Regul. Toxicol. Pharmacol. 61 (2011), S3–S12.
44. [44] Carmella, S.G., Yoder, A., Hecht, S.S., Combined analysis of r-1,t-2,3,c-4-tetrahydroxy-1,2,3,4-tetrahydrophenanthrene and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol in smokers' plasma. Cancer Epidemiol. Biomark. Prev. 15 (2006), 1490–1494.
45. [45] Hecht, S.S., Carmella, S.G., Ye, M., Le, K.A., Jensen, J.A., Zimmerman, C.L., Hatsukami, D.K., Quantitation of metabolites of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone after cessation of smokeless tobacco use. Cancer Res. 62 (2002), 129–134.
46. [46] Kramlinger, V.M., von Weymarn, L.B., Murphy, S.E., Inhibition and inactivation of cytochrome P450 2A6 and cytochrome P450 2A13 by menthofuran, beta-nicotyrine and menthol. Chem. Biol. Interact. 197 (2012), 87–92.
47. [47] Van Vleet, T.R., Bombick, D.W., Coulombe, R.A. Jr., Inhibition of human cytochrome P450 2E1 by nicotine, cotinine, and aqueous cigarette tar extract in vitro. Toxicol. Sci. 64 (2001), 185–191.
48. [48] Ordonez, P., Sierra, A.B., Camacho, O.M., Baxter, A., Banerjee, A., Waters, D., Minet, E., Nicotine, cotinine, and beta-nicotyrine inhibit NNK-induced DNA-strand break in the hepatic cell line HepaRG. Toxicol. In Vitro 28 (2014), 1329–1337.